Newspaper Publication inrespect of unaudited financials for q ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has published its unaudited financial results for the quarter ended 30th June 2025 in 'Navprabha' and 'Navhind Times' newspapers on 15th August 2025, as required under SEBI LODR regulations. Total income from operations stood at Rs. 1,671.67 lakhs, marginally down from Rs. 1,709.03 lakhs in the same quarter last year but up sharply from Rs. 1,413.85 lakhs in the preceding quarter (Q4 FY25). Net profit after tax came in at Rs. 22.33 lakhs, a 33.8% jump from Rs. 16.69 lakhs in Q1 FY25, though lower sequentially compared to Rs. 32.64 lakhs in Q4 FY25. Earnings per share stood at Rs. 0.23, up from Rs. 0.17 in the year-ago quarter. The results were reviewed by the Audit Committee and approved by the Board on 13th August 2025.
This is a routine regulatory filing for newspaper publication of already-approved results, with no new material action. YoY profit growth of ~34% on slightly lower revenue suggests margin improvement, while the sequential dip from Q4 FY25 reflects normal post-year-end adjustments. No immediate stock-moving catalyst.